High-density lipoprotein cholesterol therapies: the next frontier in lipid management

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Current guidelines prioritize low-density lipoprotein cholesterol (LDL-C) reduction using statins.
• Despite achieving LDL-C goals, coronary heart disease (CHD) remains a major cause of death.
• High-density lipoprotein cholesterol (HDL-C) is recognized as a potential therapeutic target for atherosclerosis.

Purpose of the Study:

• To review existing strategies for increasing HDL-C levels.
• To discuss novel therapeutic compounds in development that target HDL metabolism.
• To explore new avenues for reducing the burden of CHD and atherosclerosis.

Main Methods:

• Literature review of current HDL-C raising strategies.
• Analysis of emerging pharmacological compounds targeting HDL components.
• Examination of complex HDL metabolism pathways.

Main Results:

• Several established methods exist to increase HDL-C.
• New compounds targeting various aspects of HDL metabolism are under investigation.
• These novel therapies aim to provide alternative or complementary approaches to statins.

Conclusions:

• Targeting HDL-C represents a promising strategy to further reduce cardiovascular risk.
• Emerging therapies offer potential advancements in managing atherosclerosis.
• Further research into HDL metabolism is crucial for developing effective treatments.